58 stories found
An analysis compares Thermo Fisher (TMO) and Danaher (DHR) to determine which life sciences stock is better positioned in the current market. The evaluation considers various factors influencing their investment appeal.
JPMorgan notes that one of the market's 'most durable growth' sectors has been overlooked in favor of AI, listing Eli Lilly, AbbVie, and Danaher Corporation as top stock picks in that sector.
Several companies, including Charles Schwab, MSCI, Wintrust Financial, and General Motors, have released their Q2 earnings reports. While some companies like Charles Schwab beat earnings expectations, others faced disappointments, such as higher expenses.
Danaher (DHR) has finalized its acquisition of Masimo Corporation for $9.9 billion, completing a significant transaction in the life sciences and diagnostics industry.
Several financial institutions, including Truist, BMO Capital, Argus, JPMorgan, BofA, and HSBC, have reduced their price targets for various major companies such as Edison International, Alamos Gold, Ulta Beauty, Accenture, PDD Holdings, and Danaher Corporation.
A summary of the best Wall Street analyst research calls for Thursday, covering companies such as Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, and Toast.
Analysts on Wall Street have issued their top research calls for Tuesday, covering various companies including CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, and Tripadvisor.
The articles analyze several large-cap stock picks by investor Steve Cohen, including Autodesk, Atlassian, Danaher, and Sea Limited. They detail the reasons behind these selections, highlighting their potential and robust growth.
Danaher Corporation (DHR) has announced its first-quarter earnings, reporting an adjusted EPS that exceeded analyst expectations. The company's financial results for the quarter indicate stronger performance than anticipated.
Danaher Corporation has provided a summary of its earnings call for the first quarter of 2026.
The transcript for Danaher's first quarter 2026 earnings call has been released, providing details on the company's financial performance and outlook.
Despite cutting their price targets, both Barclays and Evercore analysts have maintained a positive outlook on Danaher (DHR).
Danaher (DHR) presented its projections for 2026 revenue growth at the TD Cowen 46th Annual Health Care Conference, outlining its financial outlook.
Danaher Corporation (DHR) is reportedly considering an all-cash deal for Masimo, which is seen as a strong strategic fit for the company.
Danaher's acquisition of Masimo for $9.9 billion marks one of the largest medtech buyouts anticipated for 2026.
Danaher shares fell on the news that it was acquiring medtech player Masimo.
Danaher has agreed to acquire Masimo, a medical technology firm, in a deal valued at $9.9 billion.
Danaher Strikes $10 Billion Deal for Masimo The Wall Street Journal
A list of premarket movers in the US includes Danaher, Fiserv, General Mills, Masimo, and Zim, indicating early trading activity.
Danaher is reportedly close to acquiring Masimo, a medical technology company involved in an intellectual property dispute with Apple, for nearly $10 billion.
SpaceX's first-ever earnings report since its stock market debut shows higher revenues but also significant spending, leading to a loss in the first quarter. The company's AI investments are noted as a factor in its expenditures.
The recent decline in Danaher's stock price this week is being viewed by some analysts as a potential buying opportunity for investors.
Danaher's stock experienced a slight dip despite the company reporting better-than-expected Q2 earnings and raising its guidance. The company's non-GAAP EPS of $1.94 beat estimates by $0.09, and revenue of $6.3 billion surpassed expectations by $130 million, with its Q2 earnings call highlights further detailing the performance.
Analysts are assessing whether companies like Danaher, DoorDash, and PDD Holdings are among the best non-tech stocks to buy. The evaluations focus on their investment potential outside the technology sector.
Danaher Corporation's stock recovery has reportedly failed to meet the expectations of investors.
Wolfe Research has downgraded Danaher Corporation (DHR), indicating a revised outlook on the company's stock performance.
RBC Capital has announced that it is resuming its coverage of Danaher Corporation (DHR), a move that often signals renewed analyst interest in the company.
Jim Cramer provided an analysis of Danaher's performance and compared it to its industry peers.
New analyst reports have been published for several major corporations, including Danaher Corp, American Express Co, MSCI Inc, ServiceNow Inc, and Texas Instruments Inc.
Highlights from Danaher's first-quarter earnings call have been published, detailing the company's financial results and strategic updates.
Danaher Corp. is being highlighted as a potentially smart investment opportunity within the biotechnology sector.
Evercore ISI has revised its price target for Danaher (DHR) downwards but simultaneously added the shares to its Tactical Outperform list. This mixed rating reflects a nuanced view on the company's stock performance.
The article discusses the potential future trajectory and market expectations for Danaher Corporation (DHR).
Danaher (DHR) is reportedly experiencing gains due to improvements in its bioprocessing business segment.
Danaher's strategic shift involving a $10 billion merger and acquisition move requires confidence from investors.
Danaher has announced the acquisition of Masimo for $9.9 billion, a move aimed at strengthening its diagnostics business.
The companies said on Tuesday that Danaher will pay $180 per share to buy Masimo. The offer represents a premium of 38.3% to Masimo's last close.
Danaher has acquired Masimo for $9.9 billion, a significant move in the medical technology sector.
Danaher Strikes $10 Billion Deal for Masimo The Wall Street Journal
An analysis compares the market positions of healthcare giants Johnson & Johnson and Danaher following their recent earnings reports, evaluating which stock is better positioned.
New analyst reports have been released for Northrop Grumman Corp, Danaher Corp, and Capital One Financial Corp. These reports provide financial analysis and insights into the performance of these companies.
An earnings preview outlines what to expect from Danaher's next quarterly financial report.
The article analyzes Danaher's stock performance, which is down 22% this year, and questions whether its acquisition of Masimo presents an opportune entry point for investors. It likely evaluates the acquisition's impact and future potential for the company.
Piper Sandler has begun its coverage of Danaher (DHR), while analysts anticipate new growth catalysts for the company.
Analysts on Wall Street anticipate that Danaher (DHR) will benefit from an upturn in industry conditions.
Eagle Capital Management has made a significant investment in Danaher (DHR), citing the company's potential for mid-teens earnings per share growth.
Recent financial analyses are evaluating whether Eaton Corporation plc (ETN) and Danaher Corporation (DHR) are good stocks to buy now. Investors are examining their performance and market potential.
Danaher Corporation has reached a $173 million settlement in an investor lawsuit related to its post-pandemic financial forecasts.
Danaher has provided its financial outlook for 2026, projecting adjusted earnings per share between $8.35 and $8.55, while maintaining a core growth outlook of 3% to 6%.
Danaher Corporation reported first-quarter earnings that surpassed analyst targets and subsequently raised its full-year earnings outlook. This positive financial performance occurred despite a slight miss on revenue expectations.
An overview of what to expect from Danaher Corporation's first-quarter 2026 earnings report, providing insights into the company's financial performance.
An analysis is presented comparing Danaher Corporation’s stock performance against other companies in the health care sector.
Medallion Financial aims for mid-teens loan growth by 2026, driven by an expanding home improvement segment and a leadership transition.
Masimo (MASI) shares surged 34% following the announcement of a $9.9 billion merger with Danaher.
Danaher Corp. (DHR) has indicated signs of a stable bioprocessing segment, suggesting positive performance in this area.
Warner Bros has given Paramount a week to submit its 'best and final' offer, as Netflix grants a waiver to a rival bidder in a high-stakes battle for control.
Danaher has announced its intention to acquire Masimo in a deal valued at $9.9 billion.
Danaher Corporation has announced its intention to acquire Masimo for $9.9 billion, a strategic move aimed at bolstering its diagnostics portfolio.